Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study
The efficacy and the safety of the administration of multipotent mesenchymal stromal cells (MMSCs) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic hematopoietic cell transplantation (HSCT) were studied. This prospective clinical trial was based on the random patient allo...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2012/968213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308830854283264 |
|---|---|
| author | Larisa A. Kuzmina Natalia A. Petinati Elena N. Parovichnikova Lidia S. Lubimova Elena O. Gribanova Tatjana V. Gaponova Irina N. Shipounova Oxana A. Zhironkina Alexey E. Bigildeev Daria A. Svinareva Nina J. Drize Valery G. Savchenko |
| author_facet | Larisa A. Kuzmina Natalia A. Petinati Elena N. Parovichnikova Lidia S. Lubimova Elena O. Gribanova Tatjana V. Gaponova Irina N. Shipounova Oxana A. Zhironkina Alexey E. Bigildeev Daria A. Svinareva Nina J. Drize Valery G. Savchenko |
| author_sort | Larisa A. Kuzmina |
| collection | DOAJ |
| description | The efficacy and the safety of the administration of multipotent mesenchymal stromal cells (MMSCs) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic hematopoietic cell transplantation (HSCT) were studied. This prospective clinical trial was based on the random patient allocation to the following two groups receiving (1) standard GVHD prophylaxis and (2) standard GVHD prophylaxis combined with MMSCs infusion. Bone marrow MMSCs from hematopoietic stem cell donors were cultured and administered to the recipients at doses of 0.9–1.3×106/kg when the blood counts indicated recovery. aGVHD of stage II–IV developed in 38.9% and 5.3% of patients in group 1 and group 2, respectively, (𝑃=0.002). There were no differences in the graft rejection rates, chronic GVHD development, or infectious complications. Overall mortality was 16.7% for patients in group 1 and 5.3% for patients in group 2. The efficacy and the safety of MMSC administration for aGVHD prophylaxis were demonstrated in this study. |
| format | Article |
| id | doaj-art-181e7c236c064fb2b418ccb2a4d55640 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-181e7c236c064fb2b418ccb2a4d556402025-08-20T03:54:20ZengWileyStem Cells International1687-966X1687-96782012-01-01201210.1155/2012/968213968213Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II StudyLarisa A. Kuzmina0Natalia A. Petinati1Elena N. Parovichnikova2Lidia S. Lubimova3Elena O. Gribanova4Tatjana V. Gaponova5Irina N. Shipounova6Oxana A. Zhironkina7Alexey E. Bigildeev8Daria A. Svinareva9Nina J. Drize10Valery G. Savchenko11FGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaFGBU Hematology Research Center, Russia Fedration Ministry of Public Health, 125167 Moscow, RussiaThe efficacy and the safety of the administration of multipotent mesenchymal stromal cells (MMSCs) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic hematopoietic cell transplantation (HSCT) were studied. This prospective clinical trial was based on the random patient allocation to the following two groups receiving (1) standard GVHD prophylaxis and (2) standard GVHD prophylaxis combined with MMSCs infusion. Bone marrow MMSCs from hematopoietic stem cell donors were cultured and administered to the recipients at doses of 0.9–1.3×106/kg when the blood counts indicated recovery. aGVHD of stage II–IV developed in 38.9% and 5.3% of patients in group 1 and group 2, respectively, (𝑃=0.002). There were no differences in the graft rejection rates, chronic GVHD development, or infectious complications. Overall mortality was 16.7% for patients in group 1 and 5.3% for patients in group 2. The efficacy and the safety of MMSC administration for aGVHD prophylaxis were demonstrated in this study.http://dx.doi.org/10.1155/2012/968213 |
| spellingShingle | Larisa A. Kuzmina Natalia A. Petinati Elena N. Parovichnikova Lidia S. Lubimova Elena O. Gribanova Tatjana V. Gaponova Irina N. Shipounova Oxana A. Zhironkina Alexey E. Bigildeev Daria A. Svinareva Nina J. Drize Valery G. Savchenko Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study Stem Cells International |
| title | Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study |
| title_full | Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study |
| title_fullStr | Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study |
| title_full_unstemmed | Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study |
| title_short | Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study |
| title_sort | multipotent mesenchymal stromal cells for the prophylaxis of acute graft versus host disease a phase ii study |
| url | http://dx.doi.org/10.1155/2012/968213 |
| work_keys_str_mv | AT larisaakuzmina multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT nataliaapetinati multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT elenanparovichnikova multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT lidiaslubimova multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT elenaogribanova multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT tatjanavgaponova multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT irinanshipounova multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT oxanaazhironkina multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT alexeyebigildeev multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT dariaasvinareva multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT ninajdrize multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy AT valerygsavchenko multipotentmesenchymalstromalcellsfortheprophylaxisofacutegraftversushostdiseaseaphaseiistudy |